24.07.2014 14:09
Amal Therapeutics, a Swiss biotech start-up company, and TransCure bioServices, a French preclinical contract research organization, have obtained a European Eurostars Programme grant, for a total of 1.07 million Euro. This award winning project, named HuVac, aims to use enhanced humanized immune system mouse models for vaccine development and to validate a novel therapeutic vaccine for human glioblastoma multiform (GBM).